Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-containing Treatment

NCT00248703 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT00248703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00248703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-containing Treatment
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
April 30, 2022
Enrollment
1,128 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer